GeneDx Quote - WGS

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

79.00

Bid

76.33

Ask

79.25

Volume

416,941

74.10 Day's Range 78.92

2.466 52 Week Range 89.1099

Market Cap

2.17B

Previous Close

79.45

Open

78.75

Last Trade

76.375

Last Trade Time

16:43:00

Financial Volume

US$ 31,781,148

VWAP

76.2246

Average Volume (3m)

627,781

Shares Outstanding

27,471,397

Dividend Yield

PE Ratio

-12.18

Earnings Per Share (EPS)

-6.4

Revenue

202.57M

Net Profit

-175.77M

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and... GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It also provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. is headquartered in Stamford, Connecticut. Show more

Sector

Blank Checks

Industry

Health Services

Website

www.genedx.com

Headquarters

Wilmington, Delaware, USA

Founded

2020

GeneDx Holdings Corporation is listed in the Blank Checks sector of the NASDAQ with ticker WGS. The last closing price for GeneDx was US$79.45. Over the last year, GeneDx shares have traded in a share price range of US$ 2.466 to US$ 89.1099.

GeneDx currently has 27,471,397 shares outstanding. The market capitalization of GeneDx is US$2.18 billion. GeneDx has a price to earnings ratio (PE ratio) of -12.18.

Overall Flow

Bearish

Net Premium

-27k

Calls / Puts

0.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd Annual J.P. Morgan Healthcare...

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines (Nasdaq: PRAX) and Stoke...

GeneDx to Participate in Upcoming Investor Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the Piper Sandler 36th Annual...

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today...

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (Nasdaq: WGS), a leader in delivering improved health...

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

Data demonstrates the strength of GeneDx’s diverse database; exome diagnostic rate is high regardless of patient’s ancestral background GeneDx industry leading dataset from 46% non-white...

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

Data to be presented showcasing GeneDx’s ongoing commitment to spearheading industry-leading research to drive transformational clinical utility GeneDx (Nasdaq: WGS), a leader in delivering...

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

Achieved profitability milestone with third quarter adjusted net income1 of $1.2M Reported third quarter 2024 revenues2 of $76.6M with 77% year-over-year growth of exome and genome test...

Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening

Findings published today in JAMA (Journal of the American Medical Association) reveal limitations of current screening methods and showcase the promise of advanced genomic technology to deliver...

GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns

Data to be presented at the International Conference on Newborn Sequencing (ICoNS) highlighting lessons learned from the GUARDIAN and Early Check newborn sequencing studies showcasing GeneDx’s...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	6.65	9.19143054596	72.35	81.9	72.25	396511	77.74724812	CS
4	-0.59	-0.741299158186	79.59	84.77	70.27	510196	76.85957361	CS
12	31.17	65.1683044115	47.83	89.1099	46.63	627781	72.04749087	CS
26	53.04	204.314329738	25.96	89.1099	24.91	525451	55.32982076	CS
52	75.97	2507.26072607	3.03	89.1099	2.466	446365	38.74026187	CS
156	68.077	623.244529891	10.923	89.1099	1.16	946966	18.44338773	CS
260	68.077	623.244529891	10.923	89.1099	1.16	946966	18.44338773	CS

WGS - Frequently Asked Questions (FAQ)

What is the current GeneDx share price?

The current share price of GeneDx is US$ 79.00

How many GeneDx shares are in issue?

GeneDx has 27,471,397 shares in issue

What is the market cap of GeneDx?

The market capitalisation of GeneDx is USD 2.18B

What is the 1 year trading range for GeneDx share price?

GeneDx has traded in the range of US$ 2.466 to US$ 89.1099 during the past year

What is the PE ratio of GeneDx?

The price to earnings ratio of GeneDx is -12.18

What is the cash to sales ratio of GeneDx?

The cash to sales ratio of GeneDx is 10.56

What is the reporting currency for GeneDx?

GeneDx reports financial results in USD

What is the latest annual turnover for GeneDx?

The latest annual turnover of GeneDx is USD 202.57M

What is the latest annual profit for GeneDx?

The latest annual profit of GeneDx is USD -175.77M

What is the registered address of GeneDx?

The registered address for GeneDx is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the GeneDx website address?

The website address for GeneDx is www.genedx.com

Which industry sector does GeneDx operate in?

GeneDx operates in the HEALTH SERVICES sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
VINCVincerx Inc	US$ 0.385 (98.45%)	17.37M
AERTAeries Technology Inc	US$ 1.58 (80.18%)	1.73M
CCTGCCSC Technology International Holdings Ltd	US$ 2.60 (58.54%)	2.93M
GNTAGenenta Science SPA	US$ 5.80 (18.85%)	10k
VRPXVirpax Pharmaceuticals Inc	US$ 0.4789 (16.80%)	1.85M
LITMSnow Lake Resources Ltd	US$ 1.185 (-25.94%)	3.53M
SHMDSCHMID Group NV	US$ 2.58 (-17.83%)	24.08k
XAIRBeyond Air Inc	US$ 0.38 (-13.64%)	1.45M
GTIGraphjet Technology	US$ 0.88 (-12.87%)	1.79M
SYRASyra Health Corporation	US$ 0.392 (-12.36%)	14.1k
VINCVincerx Inc	US$ 0.385 (98.45%)	17.37M
XTIAXTI Aerospace Inc	US$ 0.041 (3.80%)	9.52M
CEROCERo Therapeutics Holdings Inc	US$ 0.0697 (16.17%)	8.03M
INTZIntrusion Inc	US$ 2.05 (-5.09%)	6.89M
EYENEyenovia Inc	US$ 0.0985 (4.56%)	4.66M